Who Needs Monitoring for Tysabri-Related PML?
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Focused Risk Awareness
If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). Understanding who is at higher risk and the typical timeline of PML onset is crucial for early detection. This page reviews the key risk factors and what monitoring involves, building on a long tradition of post-market surveillance that prioritizes patient safety.
Tysabri and PML: A Documented Causal Link
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and postmarketing surveillance. The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and ataxia. Diagnosis typically involves magnetic resonance imaging (MRI) showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte adhesion and migration across the blood-brain barrier, Tysabri reduces immune surveillance in the central nervous system. This immunosuppressive effect allows latent JC virus, which is present in many individuals, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage. Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA label emphasizes that "these factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment and education about PML risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Risk Communication and Legal Implications
From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central issue. The boxed warning and the TOUCH program represent regulatory efforts to communicate risk, but questions may arise about whether patients and prescribers fully understood the magnitude of the risk, particularly in the context of evolving knowledge about risk factors. For affected patients, settlement-related considerations often involve the timeline between exposure and documented harm. PML can develop months to years after starting Tysabri, and the latency period complicates the attribution of harm to the drug. The FDA label notes that "the duration of treatment with TYSABRI prior to onset ranged from a few months to several years" for related herpes infections, and a similar variable latency applies to PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability can affect legal claims, as the statute of limitations for filing a lawsuit in New Jersey typically begins to run from the date the injury is discovered or reasonably should have been discovered. For PML, this discovery date may be the time of diagnosis, which could be significantly later than the initial exposure to Tysabri. Patients who develop PML after Tysabri treatment may face severe disability or death, and settlements in such cases often consider medical expenses, lost income, pain and suffering, and the adequacy of risk communication. The FDA label explicitly states that Tysabri "should not be used in combination with immunosuppressants or inhibitors of TNF-α" in Crohn's disease, and that physicians should consider whether the expected benefit is sufficient to offset the PML risk when initiating treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These prescribing instructions are relevant to evaluating whether the drug was used appropriately in a given case. In summary, the evidence establishes a clear causal link between Tysabri and PML, with identified risk factors and a mechanistic basis. The FDA has mandated warnings and a restricted distribution program, but the variable latency of PML and the complexity of risk assessment may influence settlement considerations. For patients in New Jersey, the statute of limitations for claims related to Tysabri-induced PML will depend on the date of diagnosis and the specific circumstances of the case. Legal consultation is recommended for affected individuals to understand their rights and the applicable deadlines.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in New Jersey?
In New Jersey, the statute of limitations for personal injury claims, including those related to Tysabri-induced PML, is generally two years from the date the injury is discovered or reasonably should have been discovered. For PML, this discovery date is typically the date of diagnosis. However, because PML can develop months to years after starting Tysabri, the exact timeline may vary. It is crucial to consult with a legal professional to determine the applicable deadline in your specific case.
What factors influence Tysabri PML settlements?
Settlements for Tysabri-related PML cases often consider medical expenses, lost income, pain and suffering, and the adequacy of risk communication. The FDA has mandated a boxed warning and a restricted distribution program (TOUCH) to communicate PML risks. However, questions may arise about whether patients and prescribers fully understood the magnitude of the risk, especially given evolving knowledge about risk factors such as anti-JCV antibodies, treatment duration, and prior immunosuppressant use. Legal consultation is recommended to evaluate the specifics of each case.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
- Statute of limitations for Tysabri in New Jersey
- FDA warning Tysabri Progressive Multifocal Leukoencephalopathy
- Virginia Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
- Statute of limitations for Tysabri in Pennsylvania
- Tysabri Progressive Multifocal Leukoencephalopathy lawsuit settlement criteria
References
Find Out If You Qualify for Compensation
Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.